SLU-PP-332

What SLU-PP-332 does

SLU-PP-332 is a small molecule, not a peptide. It activates cell switches involved in energy use and improved endurance and fat metabolism in mice. No published study has dosed people, and no human trial was registered in this search. Oral absorption is poor in preclinical work. Human benefits, safe doses and long-term harms are unknown.

• In mice, it increased how long they could run on a treadmill. (animal)
• In mice with obesity, it reduced fat gain. (animal)
• Some users report easier cardio or more training capacity, others no effect; no study has tested it in people. (Reported by users)

Uses in the sources

• Users report easier cardio or more training capacity; controlled human benefits are unproven. (Reported by users) (source)
• Users report adding it during weight loss. The controlled fat-loss evidence comes from mice. (Reported by users) (source)
• Used online for more energy; some reports instead describe fatigue or no benefit. (Reported by users) (source)

SLU-PP-332 dosage

Typical reported dose: 250 mcg once a day, 8 weeks on, 3 weeks off

• 250 micrograms with long breaks: 250 micrograms daily; reported 8 weeks on, 3 weeks off. once daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
• 500 micrograms before cardio: 500 micrograms daily. once daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
• Split capsules, twice daily: 500 micrograms twice daily; total 1,000 micrograms per day. twice daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
• Corrected report: 250 three times: 250 micrograms three times daily; total 750 micrograms per day. three times daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
• 5 mg twice daily: 5 mg twice daily; total 10 mg per day. twice daily, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)
• 60 mg reduced because of fatigue: 60 mg daily; later 40 mg morning + 20 mg pre-workout; then 20 mg morning. Later limited use to 3 sessions weekly. daily, then three training sessions per week, by mouth. Reported by users, occasional report. Studied in: Adults posting online; age, product identity and actual dose unverified. (source)

These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.

Work out syringe units with the dosing calculator

How to mix SLU-PP-332

Comes as: Community-reported capsules and tablets, Community-reported powder vials and injection mixtures, Community-reported sublingual liquids.

Mixed with: Users report bacteriostatic water with dimethyl sulfoxide (DMSO). No safe human injectable formulation or mixing method is established..

Common vial sizes: 3, 5, 10 mg. Common water amounts: 0.75, 2, 2.5 mL.

• These are reported vial sizes and water volumes, not a validated mixing recipe. Frequency in the wider community is unknown.
• SLU-PP-332 had kinetic solubility of only 0.2 micromolar in a lab assay. Ordinary peptide mixing assumptions do not apply.
• Users report clouding and precipitate after adding water. Visual clarity cannot confirm uniform dose, identity, sterility or solvent safety.
• DMSO percentages and mixing instructions conflict online. No safe subcutaneous DMSO limit was established in this research.
• Published mouse studies used laboratory solvent mixtures for abdominal-cavity injections; that route is different from injection under the skin.

Before mixing: No validated human-product storage temperature or shelf life found. Capsule users ask about refrigeration; this is not stability evidence.

After mixing: No validated shelf life in bacteriostatic water, DMSO or combined solvents. Published mouse formulations do not establish home-vial stability.

SLU-PP-332 side effects and risks

Reported side effects

• Sweating or feeling hot: community reports: Reported online; no measured incidence., moderate. Stop and seek assessment if overheating, weakness or confusion develops. (source)
• Fatigue or brain fog: community reports: Reported during higher dosing and after stopping; rates and cause unknown., moderate. Persistent or disabling symptoms need clinical assessment. (source)
• Trouble sleeping: community reports: No placebo controlled frequency estimate., moderate (source)
• Injection pain or irritation: Reported online; product and solvent contributions unknown., moderate. Hot, swollen or spreading redness needs urgent assessment. (source)
• Lightheadedness and glucose changes: Both high and low readings reported; one comment gave 2.6 mmol/L. No verified incidence., serious. Check glucose during symptoms; confusion or collapse needs emergency care. (source)
• Reduced libido: isolated high-dose report: One poster escalated to 500 mg/day orally; hormone injury was not confirmed., moderate (source)
• Menstrual or breast changes: isolated report: One female commenter; no hormone tests or causal confirmation., moderate (source)
• Nausea during multi-drug use: One tesamorelin combination report; cause uncertain., moderate (source)
• Infection or serious allergy from unregulated injections: General unapproved injection risk; no SLU PP 332 specific rate., serious (source)

Stop and get help if

• Throat or tongue swelling, wheeze or trouble breathing: Stop exposure and call emergency services now; use prescribed adrenaline if available.
• Chest pain with breathlessness, sweating or faintness: Stop and call emergency services now.
• Confusion, seizure, collapse or low glucose that does not recover: Get emergency help. Do not give food or drink to an unconscious person.
• A painful, hot, swollen injection site or spreading redness: Seek urgent same-day care; rapid breathing, faintness or severe illness needs emergency help.

Who should avoid it

• pregnant: Precaution: no pregnancy exposure, fetal safety or reproductive-toxicity data were found.
• breastfeeding: Precaution: transfer into milk and effects on a nursing infant are unknown.
• tryingToConceive: Precaution: fertility effects and a safe washout interval are unknown.
• under18: Precaution: no pediatric dosing or developmental safety studies were found.
• heartCondition: Human heart safety is unknown; a mouse heart-failure result cannot establish benefit or safety in people.
• uncontrolledBloodPressure: No human blood-pressure safety data. Heart-rate and faintness complaints appear in unverified reports.
• diabetes: Human glucose responses are unknown. Both higher and lower glucose have been reported online.
• kidneyDisease: Human clearance and dose adjustment are unknown; mouse kidney findings do not establish a kidney-safe dose.
• liverDisease: Human liver preparations break down the compound; exposure and dose adjustment with liver disease are unknown.
• activeCancer: No cancer safety studies in people were found. Effects on cell energy pathways do not establish cancer safety.
• surgeryPlanned: Tell the anesthesia team about use and all solvents. No evidence-based time to stop before surgery is known.
• testedAthlete: Prohibited at all times. Not being named in the 2026 list does not make an unapproved drug permitted.
• other: A previous serious allergic reaction to this product or its solvent should stop repeat exposure.

Interactions

• Insulin: Insulin can cause low glucose. Added SLU-PP-332 effects and insulin-adjustment rules have not been studied in people.
• Sulfonylureas: These drugs can cause low glucose. Added effects and dose-adjustment rules with SLU-PP-332 have not been studied in people.
• GLP-1 drugs and retatrutide: No human combination trial found. Users report lightheadedness and variable glucose during multi-drug use.
• Other ERR agonists: Same-target combinations have no human safety data. SLU-PP-915 is a different compound, not an oral version of SLU-PP-332.
• BAM15 and other experimental metabolic drugs: Online combinations add unstudied metabolic effects; no protective or safe stacking schedule is known.
• Piperine absorption boosters: Oil/piperine mixtures are proposed online to alter exposure. Neither absorption nor interaction risk has been measured in people.
• Warfarin and other anticoagulants: No interaction data exist. This is an uncertainty screen for drugs where exposure changes or injection bleeding matter, not a proven drug interaction.

Product quality risks

• Health Canada warns that unauthorized injectable drugs have not been assessed for safety, efficacy or quality. This is general product-risk evidence.
• Wrong identity, wrong amount, microbial contamination and unsafe excipients are risks of unauthorized drugs; their frequency for SLU-PP-332 is unknown.
• No independent retail-product survey or SLU-PP-332-specific poison-center dataset was found. Vendor certificates are not a substitute.
• Powder purity does not establish dose per capsule/vial, solvent safety, sterility or endotoxin levels.
• Cloudy or settled mixtures can have uncertain dose uniformity. A clear appearance also cannot prove injection quality.

What to expect

No human dosing study found. Ten relevant records cover animal experiments, human-derived cells, laboratory metabolism, chemical design and a preclinical review.

Key studies

• Mouse endurance: ERR activation increased treadmill endurance in mice. (source)
• Mouse obesity and metabolism: The compound reduced fat gain in mouse obesity models. (source)
• Mouse heart failure: ERR agonists improved some heart outcomes in a mouse disease model. (source)
• Aging mouse kidneys: Kidney aging markers improved in mice. (source)
• Human muscle cells in a dish: Human-derived cells responded in the lab; no one was dosed. (source)
• Oral absorption comparison: An orally active successor does not validate oral SLU-PP-332. (source)

SLU-PP-332 FAQ

• Is SLU-PP-332 FDA-approved? No approved product, label or indication found in FDA/label searches. An FDA substance identity number is not approval.
• How do people take it? By mouth, once daily. One capsule user reports this cycle; no study tested the break.. Source: reported by users, not an established dose.
• What's the difference between SLU-PP-332 and Retatrutide? SLU-PP-332: an exercise-mimicking research chemical with mouse benefits and no human dosing trials. Retatrutide: an experimental weekly injection with phase 3 weight-loss results. Why people pair them: users seek appetite control plus exercise-like energy or fat loss.
• Can I take it with Retatrutide? Users seek appetite control plus exercise-like energy or fat loss. Lightheadedness and glucose changes are reported; no human combination trial exists. Source: reported by users. Ask a doctor before combining anything.
• Is it banned in sport? Yes. It is banned in and out of competition (WADA 2026). Not named in 2026; S0 covers unapproved drugs. UKAD confirms it is already prohibited and becomes an explicit S4 example from January 1, 2027.
• How long does a mixed vial last? No validated shelf life in bacteriostatic water, DMSO or combined solvents. Published mouse formulations do not establish home-vial stability.